BioCryst Pharmaceuticals Inc. blew past a five-year high as Reddit investors rallied around a call to start a “#BioWar” on the heavily-shorted biotech that develops rare disease drugs.
The stock, which recently ended development on a Covid-19 drug, rallied as much as 36% on Monday after a poster on Reddit’s WallStreetBets forum called it “the most undervalued stock in the market” while another said a brewing #BioWar was “about sticking it to the shorts in a massive way.”
Indeed, BioCryst is a short target with about 17% of float, or $259 million, sold short, according to financial analytics firm S3 Partners. But it’s also a hedge fund pick held by the likes of Citadel and the well-known biotech outfit, Baker Bros. Advisors LP.
Before Monday’s rally, shares of BioCryst had already shrugged off the scuttling of a Covid-19 trial supported by the National Institutes of Health. The company is expected to generate less than $31 million in revenue for all of 2020.
Novavax Inc., another heavily-shorted biotech, has also garnered interest across chat forums, which could benefit funds like RA Capital Management and Perceptive Advisors, which hold stakes in the company. The stock has more than doubled in the past few trading days, albeit on key positive results for its Covid-19 vaccine candidate. The short position on Novavax stands at $1.5 billion, according to S3.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.